Corient Private Wealth LLC Boosts Stake in Fresenius Medical Care AG (NYSE:FMS)

Corient Private Wealth LLC grew its stake in shares of Fresenius Medical Care AG (NYSE:FMS) by 3.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 88,381 shares of the company’s stock after buying an additional 2,918 shares during the period. Corient Private Wealth LLC’s holdings in Fresenius Medical Care were worth $2,001,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Smartleaf Asset Management LLC lifted its stake in shares of Fresenius Medical Care by 192.8% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,224 shares of the company’s stock worth $28,000 after purchasing an additional 806 shares during the period. Wilmington Savings Fund Society FSB acquired a new stake in Fresenius Medical Care in the 3rd quarter worth about $38,000. Jones Financial Companies Lllp boosted its stake in Fresenius Medical Care by 80.5% in the 4th quarter. Jones Financial Companies Lllp now owns 4,510 shares of the company’s stock worth $102,000 after buying an additional 2,012 shares during the last quarter. Venturi Wealth Management LLC increased its stake in shares of Fresenius Medical Care by 8.4% during the 4th quarter. Venturi Wealth Management LLC now owns 5,700 shares of the company’s stock valued at $129,000 after acquiring an additional 441 shares during the last quarter. Finally, GAMMA Investing LLC lifted its holdings in shares of Fresenius Medical Care by 43.3% during the 4th quarter. GAMMA Investing LLC now owns 7,164 shares of the company’s stock worth $162,000 after acquiring an additional 2,166 shares during the period. 8.37% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

FMS has been the topic of a number of recent analyst reports. Truist Financial increased their price target on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the stock a “hold” rating in a research note on Monday, January 6th. StockNews.com raised Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. Finally, Bank of America raised Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research report on Monday, December 2nd.

Fresenius Medical Care Price Performance

FMS opened at $24.29 on Tuesday. Fresenius Medical Care AG has a 52-week low of $17.93 and a 52-week high of $25.25. The company has a 50 day moving average of $23.90 and a two-hundred day moving average of $22.42. The company has a market cap of $14.25 billion, a P/E ratio of 20.07, a P/E/G ratio of 0.76 and a beta of 0.99. The company has a quick ratio of 1.02, a current ratio of 1.37 and a debt-to-equity ratio of 0.42.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.